Skip to main content

PRA Health Sciences 在 COVID-19 新冠肺炎大流行期間透過其流動健康平台擴展遙距臨床研究支持力度

Written by Customer Service on . Posted in Public Companies.

北卡羅萊納州拉里市, March 26, 2020 (GLOBE NEWSWIRE) — 為應對持續的全球 COVID-19 新冠肺炎大流行，PRA Health Sciences 今天宣佈將擴大其行業領先的遙距醫療監控流動健康平台，同時增加數項新功能來滿足贊助商對 COVID-19 虛擬研究支持的需求。
PRA 的流動健康平台 (MHP) 可讓患者隨時隨地使用。基於應用程式的平台讓贊助商以虛擬方式做到幾乎任何可以在醫生辦公室或臨床研究中心中進行的事情。協助解決 COVID-19 的新功能旨在支持臨床試驗贊助商和參與臨床研究的研究中心，讓他們可與在目前疫情期間無法前往研究中心的患者建立聯繫及進行統籌。此外，研究中心也可部署流動應用程式，將現有傳統及紙本研究演變為更分散和不受地點限制的研究，從而在關鍵的研究時限內繼續進行醫療護理和患者評估。該流動應用程式提供專供研究人員和研究中心使用的管理者網上應用程式，以及可供患者下載的流動應用程式，讓研究中心能夠：讓患者對流動應用程式使用給予電子同意或再同意收集患者同意書，允許透過第三方速遞公司交付試驗性產品與患者遙距安排和進行視像診症利用流動調查工具為研究人員提供實時分析，以採取潛在行動PRA Health Sciences 行政副總裁兼科學總監 Kent Thoelke 表示：「隨著 COVID-19 大流行持續，患者將越來越難親身往見醫生或遵守臨床研究方案要求前往研究中心和醫院就診。同樣具挑戰性和困難的是，研究中心要有能力應對試驗患者和  COVID-19 患者需求。」 「此流動和遙距解決方案容許關鍵研究在遵照協議和法規指引的情況下繼續進行，並可在對抵抗 COVID-19 至關重要的社交疏遠和減輕對各地醫療保健系統負擔之時維持患者的安全和福祉。」該流動應用程式可以收集電子知情同意書和電子簽署，並可直接在患者的個人電話或平板電腦上提供患者報告結果。該應用程式還可透過連接裝置來收集家居醫護數據，並將這些數據用於臨床試驗。PRA 的流動健康平台是針對每個特定的試驗而構建的，可在短短一週或更短的時間內迅速部署。PRA 的臨床技術專家會根據疾病狀態、患者人口統計資料和資助對象來確定哪些功能最適合每個特定的混合或分散試驗。如欲了解有關 PRA 流動健康平台的更多資訊，請瀏覽 https://prahs.com/pra-mobile-health-platform。請按此處與我們的團隊聯絡：https://prahs.com/contact/virtual.關於 PRA HEALTH SCIENCES

 PRA (NASDAQ: PRAH) 是全球營收最高的領先環球合約研究組織之一，為生物技術和製藥業提供承包臨床開發和數據解決方案服務。PRA 的全球臨床開發平台包括位於北美、歐洲、亞洲、拉丁美洲、南非、澳洲和中東等 75 多個辦事處，在全球各地擁有 17,500 多名員工。自 2000 年以來，PRA 已在世界各地參與約 4,000 項臨床試驗。此外 PRA 還參與了不少關鍵或支持性試驗，促成美國食品及藥物管理局或國際監管機構批准超過 95 種產品。投資者查詢：InvestorRelations@prahs.com傳媒查詢：
傳訊及公共關係總監 Laurie Hurst
HurstLaurie@prahs.com, +1.919.786.8435

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.